Heart transplant candidates face an urgent bottleneck that machine perfusion technology may finally solve. While demand vastly exceeds supply, thousands of potentially viable donor hearts are discarded annually because current preservation methods cannot maintain organ viability during transport and evaluation periods.
Static cold storage, the current gold standard, limits hearts to roughly 4-6 hours of preservation time and provides no capacity to assess organ function before transplantation. Emerging machine perfusion systems fundamentally change this paradigm by actively supporting cardiac metabolism during preservation. Hypothermic machine perfusion delivers oxygenated solutions at reduced temperatures, extending viable preservation windows while minimizing cellular damage. Normothermic machine perfusion maintains hearts at body temperature in a functioning state, enabling real-time assessment of cardiac performance and potentially reconditioning damaged organs before implantation.
These technologies represent more than incremental improvements in organ logistics. Large animal studies and early clinical trials demonstrate that machine perfusion can salvage hearts from donation after cardiac death—organs previously considered unsuitable for transplantation. Normothermic regional perfusion techniques restore circulation in donors before organ procurement, expanding the donor pool substantially. European and American transplant centers adopting these methods report maintained success rates despite using previously marginal donor organs. For the estimated 40,000 Americans awaiting heart transplants, machine perfusion could transform organ availability from scarcity to sufficiency, fundamentally altering survival prospects for end-stage heart failure patients.